Analyst Michael Matson from Needham reiterated a Buy rating on Hologic (HOLX – Research Report) and keeping the price target at $90.00.

Hologic (HOLX – Research Report), the Healthcare sector company, was revisited by a Wall Street analyst yesterday. Analyst Tejas Savant ...

According to the reproductive desire of the patient and the severity of symptoms surgical procedures comprise myomectomy, endometrial ablation or hysterectomy. In 2009 the Bayer Healthcare ...

Dr Ray O’Connor takes a look at the latest clinical papers on HRT and breast cancer, and the long-term outcomes for patients ...

Johnson & Johnson MedTech will enter the U.S. pulsed field ablation market following an FDA green light for its Varipulse ...

The technology is integrated with company’s electroanatomical mapping system, which helps guide operators during AF ablation.

As Boston Scientific’s pulsed field ablation business continues to grow, the medtech aims to nourish the program with the ...

Nanoparticle-directed therapy has shown significant promise for treating localised prostate cancer, achieving tumour ablation ...

The VARIPULSE™ Platform is the first and only Pulsed Field Ablation (PFA) System in the U.S. fully integrated with the CARTO™ ...

NeuroOne will get $3 million upfront for an exclusive license to distribute its radiofrequency ablation system designed to treat neurological disorders such as epilepsy and Parkinson's disease.

The Affera mapping and ablation system is the first on the market that can deliver both pulsed-field and radiofrequency ...

Antiarrhythmic drugs (AADs) are often used after ablation for atrial fibrillation (AF); the drugs employed vary, but most common are the drugs that were unsuccessful prior to ablation since it ...